These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

492 related articles for article (PubMed ID: 25552476)

  • 1. Use and safety of intratumoral application of European mistletoe (Viscum album L) preparations in Oncology.
    Steele ML; Axtner J; Happe A; Kröz M; Matthes H; Schad F
    Integr Cancer Ther; 2015 Mar; 14(2):140-8. PubMed ID: 25552476
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune-related and adverse drug reactions to low versus high initial doses of Viscum album L. in cancer patients.
    Schad F; Thronicke A; Merkle A; Matthes H; Steele ML
    Phytomedicine; 2017 Dec; 36():54-58. PubMed ID: 29157828
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of Intravenous Application of Mistletoe (Viscum album L.) Preparations in Oncology: An Observational Study.
    Steele ML; Axtner J; Happe A; Kröz M; Matthes H; Schad F
    Evid Based Complement Alternat Med; 2014; 2014():236310. PubMed ID: 24955100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Efficacy and safety of long-term complementary treatment with standardized European mistletoe extract (Viscum album L.) in addition to the conventional adjuvant oncologic therapy in patients with primary non-metastasized mammary carcinoma. Results of a multi-center, comparative, epidemiological cohort study in Germany and Switzerland].
    Bock PR; Friedel WE; Hanisch J; Karasmann M; Schneider B
    Arzneimittelforschung; 2004; 54(8):456-66. PubMed ID: 15460213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of the long-term adjuvant treatment of primary intermediate- to high-risk malignant melanoma (UICC/AJCC stage II and III) with a standardized fermented European mistletoe (Viscum album L.) extract. Results from a multicenter, comparative, epidemiological cohort study in Germany and Switzerland.
    Augustin M; Bock PR; Hanisch J; Karasmann M; Schneider B
    Arzneimittelforschung; 2005; 55(1):38-49. PubMed ID: 15727163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intratumoral Mistletoe (Viscum album L) Therapy in Patients With Unresectable Pancreas Carcinoma: A Retrospective Analysis.
    Schad F; Atxner J; Buchwald D; Happe A; Popp S; Kröz M; Matthes H
    Integr Cancer Ther; 2014 Jul; 13(4):332-40. PubMed ID: 24363283
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of Combined Treatment With Monoclonal Antibodies and Viscum album L Preparations.
    Schad F; Axtner J; Kröz M; Matthes H; Steele ML
    Integr Cancer Ther; 2018 Mar; 17(1):41-51. PubMed ID: 29444603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiproliferative potential from aqueous Viscum album L. preparations and their main constituents in comparison with ricin and purothionin on human cancer cells.
    Felenda JE; Turek C; Stintzing FC
    J Ethnopharmacol; 2019 May; 236():100-107. PubMed ID: 30840914
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adverse Drug Reactions and Expected Effects to Therapy with Subcutaneous Mistletoe Extracts (Viscum album L.) in Cancer Patients.
    Steele ML; Axtner J; Happe A; Kröz M; Matthes H; Schad F
    Evid Based Complement Alternat Med; 2014; 2014():724258. PubMed ID: 24672577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Mistletoe (Viscum album) preparations: an optional drug for cancer patients?].
    Bar-Sela G; Gershony A; Haim N
    Harefuah; 2006 Jan; 145(1):42-6, 77. PubMed ID: 16450726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of mistletoe preparations (Viscum album) for patients with cancer diseases. A systematic review.
    Melzer J; Iten F; Hostanska K; Saller R
    Forsch Komplementmed; 2009 Aug; 16(4):217-26. PubMed ID: 19729932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retrolective, comparative, epidemiological cohort study with parallel groups design for evaluation of efficacy and safety of drugs with "well-established use".
    Bock PR; Friedel WE; Hanisch J; Karasmann M; Schneider B
    Forsch Komplementarmed Klass Naturheilkd; 2004 Aug; 11 Suppl 1():23-9. PubMed ID: 15353899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paediatric medulloblastoma cells are susceptible to Viscum album (Mistletoe) preparations.
    Zuzak TJ; Rist L; Eggenschwiler J; Grotzer MA; Viviani A
    Anticancer Res; 2006; 26(5A):3485-92. PubMed ID: 17094471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Case reports of sarcoma patients with optimized lectin-oriented mistletoe extract therapy.
    Kirsch A; Hajto T
    J Altern Complement Med; 2011 Oct; 17(10):973-9. PubMed ID: 22010781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety of higher dosages of Viscum album L. in animals and humans--systematic review of immune changes and safety parameters.
    Kienle GS; Grugel R; Kiene H
    BMC Complement Altern Med; 2011 Aug; 11():72. PubMed ID: 21871125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of viscum fraxini-2 in patients with advanced hepatocellular carcinoma.
    Mabed M; El-Helw L; Shamaa S
    Br J Cancer; 2004 Jan; 90(1):65-9. PubMed ID: 14710208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fever Therapy With Intravenously Applied Mistletoe Extracts for Cancer Patients: A Retrospective Study.
    Schläppi M; Ewald C; Kuehn JJ; Weinert T; Huber R
    Integr Cancer Ther; 2017 Dec; 16(4):479-484. PubMed ID: 27387685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Immunostimulatory properties of mistletoe extracts and their application in oncology].
    Wrotek S; Skawiński R; Kozak W
    Postepy Hig Med Dosw (Online); 2014 Oct; 68():1216-24. PubMed ID: 25380204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety of intravenously applied mistletoe extract - results from a phase I dose escalation study in patients with advanced cancer.
    Huber R; Schlodder D; Effertz C; Rieger S; Tröger W
    BMC Complement Altern Med; 2017 Sep; 17(1):465. PubMed ID: 28923036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunological response to mistletoe (Viscum album L.) in cancer patients: a four-case series.
    Gardin NE
    Phytother Res; 2009 Mar; 23(3):407-11. PubMed ID: 19003944
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.